Rodino-Klapac Louise 4

What Happened
Louise Rodino‑Klapac, President of R&D and Technical Operations at Sarepta Therapeutics, had a total of 1,399 shares withheld by the company on March 9, 2026 to satisfy tax withholding obligations tied to vested restricted stock units (RSUs). The filing reports 504 shares withheld at $16.95 each ($8,543) and 895 shares withheld at $16.95 each ($15,170), for a combined value of approximately $23,713. This was a tax-withholding disposition (routine), not an open-market sale intended as investment action.

Key Details

• Transaction date: March 9, 2026; reported on Form 4 filed March 11, 2026 (timely filing).
• Price per share: $16.95 for both withholding events.
• Shares withheld/disposed: 504 shares ($8,543) and 895 shares ($15,170); total 1,399 shares (~$23,713).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: Shares withheld to satisfy taxes on RSUs granted March 6, 2023.
  • F2: Shares withheld to satisfy taxes on RSUs granted March 7, 2022.
• Transaction code: F = tax withholding related to vesting (not a purchase or voluntary sale).

Context
This was a cashless withholding of shares to cover tax liabilities from RSU vesting—common and generally considered routine compensation-related activity rather than a signal of insider sentiment. Unlike open-market buys or voluntary sales, withheld shares do not reflect an insider choosing to convert or trade holdings.